MEDIAN Technologies to present study results at the 2012 ESMO Annual Conference
MEDIAN Technologies (ALMDT), a leading medical imaging software developer and service provider for oncology clinical trials and routine radiological practice, announced today its participation in the 2012 ESMO annual conference, to be held next Sept.28 – Oct.2, in Vienna, Austria.
MEDIAN’s scientists are presenting their results at ESMO, the European’s premier oncology conference. ‘Inter-observer agreement of the Response to Therapy Assessment in advanced Lung Cancer within a Normative Measurement Environment’ will be part of the Translation Research poster session scheduled September, 30th1:00 to 2:00 pm in Hall XL. http://abstracts.webges.com/myitinerary/day.html (Ref. 1665P).
According to MEDIAN’s findings, the tools, methods, and workflows used in image assessment can significantly impact inter-reader variability and can potentially jeopardize results in clinical studies when not designed appropriately.
The study aimed at analyzing the longitudinal assessment of medical images by several radiologists, with and without the support of both MEDIAN’s LMS software (Lesion Management Solutions) and an optimized workflow enabled by MEDIAN CTIS (Clinical Trial Imaging Services). Repeated imaging biomarker measurements were performed over time to evaluate the reliability of response assessment for cancer patients.
Study results highlight the benefits of implementing a normative measurement environment, involving advanced image analysis software tools and an optimized workflow. Automated lesion segmentation, lesion follow-up, and structured reporting capabilities significantly improved the reliability of the evaluations.
“These results provide evidence that standardization and automation shall be become the norm for the interpretation and management of images in oncology clinical trials,” said Arnaud Butzbach, CTO, VP Operations and co-founder of MEDIAN. “They also further demonstrate the significant added value of our MEDIAN LMS-CTIS offering for the biopharmaceutical industry,” he added.
MEDIAN’s scientific and business development teams will be present at booth X117 to discuss these results and to give demonstrations of MEDIAN’s LMS solutions.
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”